Neovacs : half-year report on the liquidity contract

                        REGULATED  INFORMATION ·  REGULATED  INFORMATION · REGULATED  INFORMATION

HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT

Paris and Boston, July 3, 2015 - Neovacs (Alternext Paris : ALNEV) releases its six-monthly report on the liquidity contract signed with Invest Securities.

The liquidity account had the following holdings as of June 30, 2015:

• 73,818 shares
• €119.469,22

For the prior (December 31, 2014), the corresponding figures were:
      -          76,340 shares
      -          €110,086.43

About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, please visit www.neovacs.fr

Contacts
                                                              
NEOVACS - Investor Relations
Nathalie Trépo
+33 (0)1 53 10 93 00
ntrepo@neovacs.com:
mailto:ntrepo@neovacs.com

Investor Relations / Financial Communications - NewCap
Valentine Brouchot / Pierre Laurent
+33 (0)1 44 71 94 94
neovacs@newcap.fr:
mailto:neovacs@newcap.fr